(NASDAQ: JSPR) Jasper Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.53%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32%.
Jasper Therapeutics's earnings in 2026 is -$31,771,000.On average, 8 Wall Street analysts forecast JSPR's earnings for 2026 to be -$18,780,162, with the lowest JSPR earnings forecast at -$30,000,344, and the highest JSPR earnings forecast at -$11,529,635. On average, 8 Wall Street analysts forecast JSPR's earnings for 2027 to be -$14,188,273, with the lowest JSPR earnings forecast at -$42,717,881, and the highest JSPR earnings forecast at -$3,493,829.
In 2028, JSPR is forecast to generate -$20,703,432 in earnings, with the lowest earnings forecast at -$52,826,693 and the highest earnings forecast at -$3,144,446.